Krystal Biotech Inc
NASDAQ:KRYS
Krystal Biotech Inc
NASDAQ:KRYS
Price:
159.67 USD
4.28%
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
KRYS
stock under the Base Case scenario is
113.23
USD.
Compared to the current market price of 159.67 USD,
Krystal Biotech Inc
is
Overvalued by 29%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
KRYS
Relative Value
Base Case
113.23
USD
Overvaluation 29%
Valuation Multiples
Multiples Across Competitors
KRYS Competitors Multiples
Krystal Biotech Inc Competitors
Krystal Biotech Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
4.5B USD | 88.9 | 412.4 | -43.1 | -40.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.8B USD | 7.5 | 25 | 16.6 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.6B AUD | 6.1 | 35 | 21.2 | 26.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.5 | -8.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 27 | 14.6 | 18.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
